Rapid Blood Test Can Rule Out Serious Childhood Infections
By LabMedica International staff writers Posted on 19 Oct 2016 |

Image: The Afinion C-reactive protein (CRP) test cartridge and Afinion AS100 analyzer (Photo courtesy of Alere).
The care for acutely ill children has traditionally been a primary care responsibility, but increasing numbers are being seen in secondary care, but a simple decision rule and a finger prick to test blood, general practitioners can now detect serious infections in children very quickly.
The introduction of better diagnostic tests might strengthen the primary care management of acutely ill children and inflammatory markers such as C-reactive protein (CRP) and procalcitonin can assist in diagnosing serious infections in hospital settings.
Scientists at the University of Leuven (Belgium) and their colleagues assessed a whether performing point-of-care CRP testing should be done in all children presenting with acute infection in primary care or only in those deemed at high-risk of serious illness after initial clinical assessment. They also investigated how CRP results should be interpreted; specifically, whether a low CRP level can rule out infection and the consequent need for hospital referral.
A cluster randomized controlled trial was carried out involving acutely ill children presenting to 133 general practitioners (GPs) at 78 GP practices in Belgium. Practices were randomized to undertake point-of-care CRP testing in all children (1,730 episodes) or restricted to children identified as at clinical risk (1,417 episodes). In the “CRP only if at clinical risk” group, CRP testing was dependent on the presence of at least one of the following clinical features: breathlessness, body temperature of at least 40 °C, diarrhea in children 12–30 months of age, and clinician concern. The Afinion CRP Test Cartridge (Alere, Waltham, MA, USA) was used, which has a measuring range for CRP of 5–200 mg/L and requires 1.5 μL of blood obtained by finger prick, providing a result within four minutes. They trained all physicians to perform the CRP test.
The investigators found that t restricting CRP testing to children at clinical risk (because of breathlessness, temperature equal to or greater than 40 °C, diarrhea and age 12 to 30 months, or clinician concern) substantially reduced the number of children tested to 285/1,417. The team reported that restricting CRP testing to those identified as at clinical risk increased the median CRP level of the children tested from 7 mg/L to 11 mg/L. Time from onset of fever did not influence the median point-of-care CRP level.
Jan Y. Verbakel, MD, PhD, a general practitioner and lead author of the study said, “As a result, serious infections tend to stay off the general practitioner's radar for too long. We asked ourselves how rapid diagnostic tests might help solve this problem. Thanks to the combination of a clinical examination of the patient, possibly followed by a point-of- care CRP test, general practitioners can detect serious infections more quickly and more objectively. And for children who are less seriously ill, the procedure prevents unnecessary hospital referrals and anxiety. The point-of-care CRP test is a valuable tool for general practitioners, but it has to be used responsibly.” The study was published on October 6, 2016, in the journal BMC Medicine.
Related Links:
University of Leuven
Alere
The introduction of better diagnostic tests might strengthen the primary care management of acutely ill children and inflammatory markers such as C-reactive protein (CRP) and procalcitonin can assist in diagnosing serious infections in hospital settings.
Scientists at the University of Leuven (Belgium) and their colleagues assessed a whether performing point-of-care CRP testing should be done in all children presenting with acute infection in primary care or only in those deemed at high-risk of serious illness after initial clinical assessment. They also investigated how CRP results should be interpreted; specifically, whether a low CRP level can rule out infection and the consequent need for hospital referral.
A cluster randomized controlled trial was carried out involving acutely ill children presenting to 133 general practitioners (GPs) at 78 GP practices in Belgium. Practices were randomized to undertake point-of-care CRP testing in all children (1,730 episodes) or restricted to children identified as at clinical risk (1,417 episodes). In the “CRP only if at clinical risk” group, CRP testing was dependent on the presence of at least one of the following clinical features: breathlessness, body temperature of at least 40 °C, diarrhea in children 12–30 months of age, and clinician concern. The Afinion CRP Test Cartridge (Alere, Waltham, MA, USA) was used, which has a measuring range for CRP of 5–200 mg/L and requires 1.5 μL of blood obtained by finger prick, providing a result within four minutes. They trained all physicians to perform the CRP test.
The investigators found that t restricting CRP testing to children at clinical risk (because of breathlessness, temperature equal to or greater than 40 °C, diarrhea and age 12 to 30 months, or clinician concern) substantially reduced the number of children tested to 285/1,417. The team reported that restricting CRP testing to those identified as at clinical risk increased the median CRP level of the children tested from 7 mg/L to 11 mg/L. Time from onset of fever did not influence the median point-of-care CRP level.
Jan Y. Verbakel, MD, PhD, a general practitioner and lead author of the study said, “As a result, serious infections tend to stay off the general practitioner's radar for too long. We asked ourselves how rapid diagnostic tests might help solve this problem. Thanks to the combination of a clinical examination of the patient, possibly followed by a point-of- care CRP test, general practitioners can detect serious infections more quickly and more objectively. And for children who are less seriously ill, the procedure prevents unnecessary hospital referrals and anxiety. The point-of-care CRP test is a valuable tool for general practitioners, but it has to be used responsibly.” The study was published on October 6, 2016, in the journal BMC Medicine.
Related Links:
University of Leuven
Alere
Latest Clinical Chem. News
- Carbon Nanotubes Help Build Highly Accurate Sensors for Continuous Health Monitoring
- Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples
- AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood
- Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva
- Biosensing Technology Breakthrough Paves Way for New Methods of Early Disease Detection
- New Saliva Test Rapidly Identifies Paracetamol Overdose
- POC Saliva Testing Device Predicts Heart Failure in 15 Minutes
- Screening Tool Detects Multiple Health Conditions from Single Blood Drop
- Integrated Chemistry and Immunoassay Analyzer with Extensive Assay Menu Offers Flexibility, Scalability and Data Commutability
- Rapid Drug Test to Improve Treatment for Patients Presenting to Hospital
- AI Model Detects Cancer at Lightning Speed through Sugar Analyses
- First-Ever Blood-Powered Chip Offers Real-Time Health Monitoring
- New ADLM Guidance Provides Expert Recommendations on Clinical Testing For Respiratory Viral Infections
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
Channels
Molecular Diagnostics
view channel
RNA-Based Blood Test Detects Preeclampsia Risk Months Before Symptoms
Preeclampsia remains a major cause of maternal morbidity and mortality, as well as preterm births. Despite current guidelines that aim to identify pregnant women at increased risk of preeclampsia using... Read more
First Of Its Kind Test Uses microRNAs to Predict Toxicity from Cancer Therapy
Many men with early-stage prostate cancer receive stereotactic body radiotherapy (SBRT), a highly precise form of radiation treatment that is completed in just five sessions. Compared to traditional radiation,... Read more
Novel Cell-Based Assay Provides Sensitive and Specific Autoantibody Detection in Demyelination
Anti-myelin-associated glycoprotein (MAG) antibodies serve as markers for an autoimmune demyelinating disorder that affects the peripheral nervous system, leading to sensory impairment. Anti-MAG-IgM antibodies... Read moreHematology
view channel
New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
Clonal cytopenia of undetermined significance (CCUS) is a blood disorder commonly found in older adults, characterized by mutations in blood cells and a low blood count, but without any obvious cause or... Read more
Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
In the United States, approximately 15% of pregnant individuals are RhD-negative. However, in about 40% of these cases, the fetus is also RhD-negative, making the administration of RhoGAM unnecessary.... Read moreImmunology
view channel
Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer
Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more
Machine Learning-Enabled Blood Test Predicts Immunotherapy Response in Lymphoma Patients
Chimeric antigen receptor (CAR) T-cell therapy has emerged as one of the most promising recent developments in the treatment of blood cancers. However, over half of non-Hodgkin lymphoma (NHL) patients... Read moreMicrobiology
view channel
Handheld Device Deliver Low-Cost TB Results in Less Than One Hour
Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more
New AI-Based Method Improves Diagnosis of Drug-Resistant Infections
Drug-resistant infections, particularly those caused by deadly bacteria like tuberculosis and staphylococcus, are rapidly emerging as a global health emergency. These infections are more difficult to treat,... Read more
Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours
Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read morePathology
view channel
Advanced Imaging Reveals Mechanisms Causing Autoimmune Disease
Myasthenia gravis, an autoimmune disease, leads to muscle weakness that can affect a range of muscles, including those needed for basic actions like blinking, smiling, or moving. Researchers have long... Read more
AI Model Effectively Predicts Patient Outcomes in Common Lung Cancer Type
Lung adenocarcinoma, the most common form of non-small cell lung cancer (NSCLC), typically adopts one of six distinct growth patterns, often combining multiple patterns within a single tumor.... Read moreTechnology
view channel
Pain-On-A-Chip Microfluidic Device Determines Types of Chronic Pain from Blood Samples
Chronic pain is a widespread condition that remains difficult to manage, and existing clinical methods for its treatment rely largely on self-reporting, which can be subjective and especially problematic... Read more
Innovative, Label-Free Ratiometric Fluorosensor Enables More Sensitive Viral RNA Detection
Viruses present a major global health risk, as demonstrated by recent pandemics, making early detection and identification essential for preventing new outbreaks. While traditional detection methods are... Read moreIndustry
view channel
Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions
Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Grifols and Tecan’s IBL Collaborate on Advanced Biomarker Panels
Grifols (Barcelona, Spain), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, is expanding its offer in clinical diagnostics through a strategic partnership... Read more